Why the study?
Although flecainide demonstrates therapeutic efficacy in CPVT, its underlying mechanism of action remains disputed between direct RyR2 inhibition and indirect effects via sodium channel blockade.
This commentary highlights the ongoing debate regarding whether flecainide treats CPVT through direct RyR2 modulation or indirect sodium channel blockade, which has implications for understanding anti-arrhythmic mechanisms.
No takes yet. Share an insight, caveat, or question.
Uncertainty over flecainide mechanism in CPVT warrants clinical caution; leaves open whether RyR2 or sodium blockade predominates.
Davidson et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: